(Q46646029)

23 December 2017

title

Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. (English)

1 reference

23 December 2017

author name string

Koichiro Kusumoto

1

1 reference

23 December 2017

Hiroshi Yatsuhashi

2

1 reference

23 December 2017

Rumiko Nakao

3

1 reference

23 December 2017

Rumiko Hamada

4

1 reference

23 December 2017

Mika Fukuda

5

1 reference

23 December 2017

Yoko Tamada

6

1 reference

23 December 2017

Naota Taura

7

1 reference

23 December 2017

Atsumasa Komori

8

1 reference

23 December 2017

Manabu Daikoku

9

1 reference

23 December 2017

Keisuke Hamasaki

10

1 reference

23 December 2017

Kazuhiko Nakao

11

1 reference

23 December 2017

Hiromi Ishibashi

12

1 reference

23 December 2017

Yuzo Miyakawa

13

1 reference

23 December 2017

Katsumi Eguchi

14

1 reference

23 December 2017

publication date

1 May 2008

1 reference

23 December 2017

Journal of Gastroenterology and Hepatology

published in

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

790-793

1 reference

23 December 2017

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Clinical relevance of hepatitis B viral mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Classifying hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

Diagnosis and management of pre-core mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05391.X

10.1111/J.1440-1746.2008.05391.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017